EGFR and glioblastoma: Since EGFR modifications and/or focal amplification has been identified in 57% of GBM patients [6] and 67% of patients with EGFR amplification also express EGFRvIII [45], D2C7-IT will likely demonstrate clinical efficacy and will impact GBM therapy.